Diligence memo · auto-generated · as of July 2, 2026
Egalet Corp
Egalet Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Egalet Corp operates in Pharmaceuticals, based in WAYNE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Egalet Corp has raised $42M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $42M on 2019-01-31.
Most recent recorded round closed around 2019-01-31.
Valuation (modeled)modeled
Provath models Egalet Corp at approximately $1.5B (range $137M–$3.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.89× the median modeled value of Series C Pharmaceuticals companies in 2019–2021 (33 peers) — value vs value, same stage and era. Within the normal band (89% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.4 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 79% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Verastem, Inc., Sentia Wellness, Inc., Oyster Point Pharma, Inc., Terns Pharmaceuticals, Inc., Theseus Pharmaceuticals, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.